CA2709561A1

CA2709561A1 - Therapeutic regimens for the treatment of immunoinflammatory disorders

Therapeutic regimens for the treatment of immunoinflammatory disorders Download PDF

Info

Publication number: CA2709561A1
Authority: CA; Canada
Prior art keywords: dipyridamole; formulated; prednisolone; unit dosage; dosage form
Prior art date: 2007-12-17
Legal status : Abandoned

Application number

CA2709561A

Other languages

English (en)

French (fr)

Inventor

Mahesh V. Padval

Current Assignee

Zalicus Inc

Original Assignee

Individual

Priority date

2007-12-17

Filing date

2008-12-17

Publication date

2009-06-25

2008-12-17 Application filed by Individual filed Critical Individual

2009-06-25 Publication of CA2709561A1 publication Critical patent/CA2709561A1/en

Status Abandoned legal-status Critical Current

Links

230000000495 immunoinflammatory effect Effects 0.000 title claims abstract description 14
238000011282 treatment Methods 0.000 title claims description 16
238000011285 therapeutic regimen Methods 0.000 title 1
229960002768 dipyridamole Drugs 0.000 claims abstract description 169
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims abstract description 168
239000011324 bead Substances 0.000 claims abstract description 110
238000013270 controlled release Methods 0.000 claims abstract description 60
238000000034 method Methods 0.000 claims abstract description 58
239000002552 dosage form Substances 0.000 claims abstract description 56
239000002253 acid Substances 0.000 claims abstract description 17
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 129
229960005205 prednisolone Drugs 0.000 claims description 129
238000000576 coating method Methods 0.000 claims description 112
239000011248 coating agent Substances 0.000 claims description 106
239000003246 corticosteroid Substances 0.000 claims description 71
239000000203 mixture Substances 0.000 claims description 65
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 62
239000011975 tartaric acid Substances 0.000 claims description 62
235000002906 tartaric acid Nutrition 0.000 claims description 62
239000008194 pharmaceutical composition Substances 0.000 claims description 43
239000012729 immediate-release (IR) formulation Substances 0.000 claims description 41
229920003141 Eudragit® S 100 Polymers 0.000 claims description 35
238000009472 formulation Methods 0.000 claims description 35
229920003139 Eudragit® L 100 Polymers 0.000 claims description 33
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 28
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 28
238000004090 dissolution Methods 0.000 claims description 22
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
238000000338 in vitro Methods 0.000 claims description 16
238000010521 absorption reaction Methods 0.000 claims description 10
239000002609 medium Substances 0.000 claims description 9
239000008363 phosphate buffer Substances 0.000 claims description 9
229960004618 prednisone Drugs 0.000 claims description 9
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 9
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 8
229960004436 budesonide Drugs 0.000 claims description 8
201000010099 disease Diseases 0.000 claims description 8
229960002537 betamethasone Drugs 0.000 claims description 7
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 7
229960002714 fluticasone Drugs 0.000 claims description 7
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 7
229960004584 methylprednisolone Drugs 0.000 claims description 7
238000012360 testing method Methods 0.000 claims description 7
229960001145 deflazacort Drugs 0.000 claims description 6
FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 claims description 6
239000012738 dissolution medium Substances 0.000 claims description 6
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims description 5
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 5
229920003136 Eudragit® L polymer Polymers 0.000 claims description 3
230000002618 waking effect Effects 0.000 claims description 2
229920000609 methyl cellulose Polymers 0.000 claims 2
239000001923 methylcellulose Substances 0.000 claims 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 93
239000000243 solution Substances 0.000 description 72
239000002775 capsule Substances 0.000 description 68
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 67
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 65
238000004519 manufacturing process Methods 0.000 description 47
229920003081 Povidone K 30 Polymers 0.000 description 41
239000012530 fluid Substances 0.000 description 40
239000008188 pellet Substances 0.000 description 38
239000000725 suspension Substances 0.000 description 36
239000000454 talc Substances 0.000 description 36
229910052623 talc Inorganic materials 0.000 description 36
239000007921 spray Substances 0.000 description 33
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 31
229940079593 drug Drugs 0.000 description 31
239000003814 drug Substances 0.000 description 31
239000001069 triethyl citrate Substances 0.000 description 31
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 31
235000013769 triethyl citrate Nutrition 0.000 description 31
239000008213 purified water Substances 0.000 description 25
238000003756 stirring Methods 0.000 description 24
239000002904 solvent Substances 0.000 description 21
-1 45 mg Chemical compound 0.000 description 20
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 20
229920000036 polyvinylpyrrolidone Polymers 0.000 description 19
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
230000003111 delayed effect Effects 0.000 description 18
239000011230 binding agent Substances 0.000 description 17
239000006185 dispersion Substances 0.000 description 17
239000000546 pharmaceutical excipient Substances 0.000 description 17
230000008569 process Effects 0.000 description 17
239000001267 polyvinylpyrrolidone Substances 0.000 description 16
238000002360 preparation method Methods 0.000 description 16
229920003134 Eudragit® polymer Polymers 0.000 description 15
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 15
229920002678 cellulose Polymers 0.000 description 15
239000001913 cellulose Substances 0.000 description 15
235000010980 cellulose Nutrition 0.000 description 15
230000006870 function Effects 0.000 description 15
238000011068 loading method Methods 0.000 description 15
150000001875 compounds Chemical class 0.000 description 14
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 13
239000004615 ingredient Substances 0.000 description 12
230000004584 weight gain Effects 0.000 description 12
235000019786 weight gain Nutrition 0.000 description 12
238000001035 drying Methods 0.000 description 11
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 10
239000003085 diluting agent Substances 0.000 description 10
230000002572 peristaltic effect Effects 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
235000021152 breakfast Nutrition 0.000 description 9
229960001334 corticosteroids Drugs 0.000 description 9
208000035475 disorder Diseases 0.000 description 9
229960000890 hydrocortisone Drugs 0.000 description 9
229920006316 polyvinylpyrrolidine Polymers 0.000 description 9
238000005507 spraying Methods 0.000 description 9
229920003083 Kollidon® VA64 Polymers 0.000 description 8
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 8
229960003943 hypromellose Drugs 0.000 description 8
150000003839 salts Chemical class 0.000 description 8
239000000126 substance Substances 0.000 description 8
108010010803 Gelatin Proteins 0.000 description 7
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 7
239000008186 active pharmaceutical agent Substances 0.000 description 7
239000012467 final product Substances 0.000 description 7
239000008273 gelatin Substances 0.000 description 7
229920000159 gelatin Polymers 0.000 description 7
235000019322 gelatine Nutrition 0.000 description 7
235000011852 gelatine desserts Nutrition 0.000 description 7
239000004014 plasticizer Substances 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
229920001688 coating polymer Polymers 0.000 description 6
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
229920000642 polymer Polymers 0.000 description 6
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 5
239000001856 Ethyl cellulose Substances 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
235000019325 ethyl cellulose Nutrition 0.000 description 5
229920001249 ethyl cellulose Polymers 0.000 description 5
239000013029 homogenous suspension Substances 0.000 description 5
235000012054 meals Nutrition 0.000 description 5
238000004806 packaging method and process Methods 0.000 description 5
238000012545 processing Methods 0.000 description 5
230000001681 protective effect Effects 0.000 description 5
BHDHELFREODRJK-XRYUJSLGSA-N (8s,9r,10s,13s,14s,17r)-9-fluoro-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,12,14,15,16-octahydro-1h-cyclopenta[a]phenanthrene-3,11-dione Chemical compound O=C1CC[C@]2(C)[C@@]3(F)C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 BHDHELFREODRJK-XRYUJSLGSA-N 0.000 description 4
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 4
WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 4
MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 description 4
ZOCUOMKMBMEYQV-GSLJADNHSA-N 9alpha-Fluoro-11beta,17alpha,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ZOCUOMKMBMEYQV-GSLJADNHSA-N 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
206010019233 Headaches Diseases 0.000 description 4
HHZQLQREDATOBM-CODXZCKSSA-M Hydrocortisone Sodium Succinate Chemical compound [Na+].O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 HHZQLQREDATOBM-CODXZCKSSA-M 0.000 description 4
FOGXJPFPZOHSQS-AYVLZSQQSA-N Hydrocortisone butyrate propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O FOGXJPFPZOHSQS-AYVLZSQQSA-N 0.000 description 4
DLVOSEUFIRPIRM-KAQKJVHQSA-N Hydrocortisone cypionate Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(CCC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCC1CCCC1 DLVOSEUFIRPIRM-KAQKJVHQSA-N 0.000 description 4
229920000881 Modified starch Polymers 0.000 description 4
HYRKAAMZBDSJFJ-LFDBJOOHSA-N Paramethasone acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]2(C)C[C@@H]1O HYRKAAMZBDSJFJ-LFDBJOOHSA-N 0.000 description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
RACDDTQBAFEERP-PLTZVPCUSA-N [2-[(6s,8s,9s,10r,13s,14s,17r)-6-chloro-17-hydroxy-10,13-dimethyl-3,11-dioxo-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate Chemical compound C1([C@@H](Cl)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)COC(=O)C)(O)[C@@]2(C)CC1=O RACDDTQBAFEERP-PLTZVPCUSA-N 0.000 description 4
SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 4
CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 4
ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 4
RYJIRNNXCHOUTQ-OJJGEMKLSA-L cortisol sodium phosphate Chemical compound [Na+].[Na+].O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 RYJIRNNXCHOUTQ-OJJGEMKLSA-L 0.000 description 4
BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 4
235000013305 food Nutrition 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
231100000869 headache Toxicity 0.000 description 4
229960001067 hydrocortisone acetate Drugs 0.000 description 4
229960003331 hydrocortisone cypionate Drugs 0.000 description 4
229960002846 hydrocortisone probutate Drugs 0.000 description 4
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 4
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 4
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 4
PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 4
239000006187 pill Substances 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
229920003084 Avicel® PH-102 Polymers 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
239000004698 Polyethylene Substances 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
229940092705 beclomethasone Drugs 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
235000014121 butter Nutrition 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229960003957 dexamethasone Drugs 0.000 description 3
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
229940126534 drug product Drugs 0.000 description 3
239000011094 fiberboard Substances 0.000 description 3
229960000676 flunisolide Drugs 0.000 description 3
229960000289 fluticasone propionate Drugs 0.000 description 3
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
229960001810 meprednisone Drugs 0.000 description 3
PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
239000007896 modified release capsule Substances 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
201000008482 osteoarthritis Diseases 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
229920000573 polyethylene Polymers 0.000 description 3
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
208000017520 skin disease Diseases 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
229960005294 triamcinolone Drugs 0.000 description 3
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 3
229960002117 triamcinolone acetonide Drugs 0.000 description 3
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 3
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 3
JQNVCUBPURTQPQ-UHFFFAOYSA-N (25R)-Inokosterone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(CO)C)CCC33O)C)C3=CC(=O)C21 JQNVCUBPURTQPQ-UHFFFAOYSA-N 0.000 description 2
ITMUUFDDBRYVNJ-VOKXYEOFSA-N (2S,4R)-2,16,20,25-tetrahydroxy-9beta,10,14-trimethyl-4,9-cyclo-9,10-seco-16alpha-cholest-5-ene-1,11,22-trione Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)CCC(C)(O)C)C=C2[C@H]1C[C@H](O)C(=O)C2(C)C ITMUUFDDBRYVNJ-VOKXYEOFSA-N 0.000 description 2
IWQKGRNFKYKJHS-UHFFFAOYSA-N (2alpha,3beta,12beta)-2,3,12-Trihydroxypregna-4,7,16-trien-20-one Natural products OC1C(O)CC2(C)C(CC(O)C3(C(C(=O)C)=CCC33)C)C3=CCC2=C1 IWQKGRNFKYKJHS-UHFFFAOYSA-N 0.000 description 2
GTEBNRQRSIJPHQ-XFFWNHRZSA-N (2s,4ar,6ar,6as,6br,8ar,10s,12as)-10-hydroxy-2,6a,6b,9,9,12a-hexamethyl-13-oxo-3,4,4a,5,6,6a,7,8,8a,10,11,12-dodecahydropicene-2-carboxylic acid Chemical compound O=C([C@H]12)C=C3C4=C[C@@](C)(C(O)=O)CC[C@H]4CC[C@@]3(C)[C@]2(C)CC[C@@H]2[C@]1(C)CC[C@H](O)C2(C)C GTEBNRQRSIJPHQ-XFFWNHRZSA-N 0.000 description 2
YCTXVPCDHZMBHX-QCDSSADQSA-N (4ar,5r,6ar,6bs,8ar,12ar,14ar,14br)-5-hydroxy-4,4,6a,6b,8a,11,11,14b-octamethyl-2,4a,5,6,7,8,9,10,12,12a,14,14a-dodecahydro-1h-picen-3-one Chemical compound C1CC(=O)C(C)(C)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C YCTXVPCDHZMBHX-QCDSSADQSA-N 0.000 description 2
SYVXMCCIFBTGFR-RJZNOWKXSA-N (5r,8s,10s,13s,14s,16s,17r)-17-acetyl-17-hydroxy-10,13,16-trimethyl-2,4,5,6,7,8,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C([C@H]1CC[C@H]23)C(=O)CC[C@]1(C)C2=CC[C@@]1(C)[C@H]3C[C@H](C)[C@]1(O)C(C)=O SYVXMCCIFBTGFR-RJZNOWKXSA-N 0.000 description 2
GNFTWPCIRXSCQF-UHFFFAOYSA-N (6alpha,11beta,17alphaOH)-6,11,17,21-Tetrahydroxypregn-4-ene-3,20-dione Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CC(O)C2=C1 GNFTWPCIRXSCQF-UHFFFAOYSA-N 0.000 description 2
IOYKCORNMBALAV-JMDVUPONSA-N (6r,8r,9s,10r,13s,14s,17r)-6,17-dihydroxy-17-[(1s)-1-hydroxyethyl]-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1([C@H](O)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@]([C@@H](O)C)(O)[C@@]2(C)CC1 IOYKCORNMBALAV-JMDVUPONSA-N 0.000 description 2
RVBSTEHLLHXILB-QODHSQIYSA-N (6r,8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-6,11,17-trihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound C1([C@H](O)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O RVBSTEHLLHXILB-QODHSQIYSA-N 0.000 description 2
BSVNAPJPBOKGSU-JJKSKHOQSA-N (6r,8s,9s,10r,11s,13s,14s,17s)-6,11-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3C[C@@H](O)C2=C1 BSVNAPJPBOKGSU-JJKSKHOQSA-N 0.000 description 2
FQWLSWNUHFREIQ-PJHHCJLFSA-N (6s,8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 FQWLSWNUHFREIQ-PJHHCJLFSA-N 0.000 description 2
VDNZZIYSCXESNI-ILSZZQPISA-N (6s,8s,9s,10r,11s,13s,14s,17s)-17-acetyl-11-hydroxy-6,10,13-trimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 VDNZZIYSCXESNI-ILSZZQPISA-N 0.000 description 2
UKVVNEHFNYKGMX-WHMNXGKUSA-N (8r,9s,10r,13s)-14-hydroxy-10,13-dimethyl-2,7,8,9,11,12,15,16-octahydro-1h-cyclopenta[a]phenanthrene-3,6,17-trione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)C4(O)[C@@H]3CC(=O)C2=C1 UKVVNEHFNYKGMX-WHMNXGKUSA-N 0.000 description 2
FWKZKCGCFQKDQY-KCTPXNJMSA-N (8r,9s,10r,13s,14s,15r,17r)-17-acetyl-15,17-dihydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1[C@H](O)C[C@@](C(=O)C)(O)[C@@]1(C)CC2 FWKZKCGCFQKDQY-KCTPXNJMSA-N 0.000 description 2
DBPWSSGDRRHUNT-SJFWLOONSA-N (8r,9s,10r,13s,14s,17s)-17-acetyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-SJFWLOONSA-N 0.000 description 2
ARJWMUSCDIJFLB-GVVDHYSOSA-N (8s,10s,13s,14s,17r)-17-acetyl-17-hydroxy-10,13-dimethyl-2,6,7,8,12,14,15,16-octahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 ARJWMUSCDIJFLB-GVVDHYSOSA-N 0.000 description 2
SHJZUHWENQCCJH-YQAXKJAASA-N (8s,9r,10s,11s,13s,14s)-9-fluoro-11-hydroxy-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 SHJZUHWENQCCJH-YQAXKJAASA-N 0.000 description 2
IKGBPSZWCRRUQS-DTAAKRQUSA-N (8s,9r,10s,11s,13s,14s,16s,17r)-17-acetyl-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(C)=O)(O)[C@@]1(C)C[C@@H]2O IKGBPSZWCRRUQS-DTAAKRQUSA-N 0.000 description 2
OFSXGKOMEGSTSE-BPSSIEEOSA-N (8s,9r,10s,11s,13s,14s,17r)-17-acetyl-9-fluoro-11,17-dihydroxy-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)C[C@@H]2O OFSXGKOMEGSTSE-BPSSIEEOSA-N 0.000 description 2
ZCAYUOKEIPMTMF-JPDWDDBRSA-N (8s,9s,10r,11r,13s,14s,16r,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@H]2O ZCAYUOKEIPMTMF-JPDWDDBRSA-N 0.000 description 2
IOKVWBWSLVVBRO-HXOHHMPKSA-N (8s,9s,10r,11s,13r,14s,17s)-17-acetyl-11-hydroxy-10-methyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-13-carbaldehyde Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C=O)C[C@@H]2O IOKVWBWSLVVBRO-HXOHHMPKSA-N 0.000 description 2
MAAGHJOYEMWLNT-CWNVBEKCSA-N (8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-16-methylidene-1,2,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](C(=C)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C=CC2=C1 MAAGHJOYEMWLNT-CWNVBEKCSA-N 0.000 description 2
KQZSMOGWYFPKCH-UJPCIWJBSA-N (8s,9s,10r,11s,13s,14s,17r)-17-acetyl-11,17-dihydroxy-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)C[C@@H]2O KQZSMOGWYFPKCH-UJPCIWJBSA-N 0.000 description 2
FPYGQPQXGSIDSF-RBWSHPMZSA-N (8s,9s,10r,13s,14s,17r)-17-hydroxy-17-(2-hydroxyacetyl)-13-(hydroxymethyl)-10-methyl-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,11-dione Chemical compound C([C@]1(CO)[C@@](O)(C(=O)CO)CC[C@H]1[C@@H]1CC2)C(=O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 FPYGQPQXGSIDSF-RBWSHPMZSA-N 0.000 description 2
OIGPMJCLTDSPPN-KAHGZSNJSA-N (8s,9s,10r,13s,14s,17r)-17-hydroxy-17-(2-hydroxyacetyl)-2,10,13-trimethyl-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,11-dione Chemical compound C([C@]1(C)[C@@](O)(C(=O)CO)CC[C@H]11)C(=O)[C@H]2[C@H]1CCC1=CC(=O)C(C)C[C@@]12C OIGPMJCLTDSPPN-KAHGZSNJSA-N 0.000 description 2
IDIHGZAZUJGAEB-VMXMFDLUSA-N (9r,10r,13s,17r)-17-acetyl-17-hydroxy-10,13-dimethyl-2,9,11,12,15,16-hexahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2C1=C1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 IDIHGZAZUJGAEB-VMXMFDLUSA-N 0.000 description 2
IWQKGRNFKYKJHS-KQFCJCSDSA-N 1-[(2r,3r,9s,10r,12r,13s,14s)-2,3,12-trihydroxy-10,13-dimethyl-2,3,6,9,11,12,14,15-octahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound O[C@H]1[C@H](O)C[C@]2(C)[C@@H](C[C@@H](O)[C@@]3(C(C(=O)C)=CC[C@H]33)C)C3=CCC2=C1 IWQKGRNFKYKJHS-KQFCJCSDSA-N 0.000 description 2
GAIHSQSRHYQICG-DACBVQKSSA-N 1-[(6s,8r,9s,10r,13s,14s,17r)-17-hydroxy-6,10,13-trimethyl-1,2,3,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C([C@@]12C)CCC=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 GAIHSQSRHYQICG-DACBVQKSSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
FUFLCEKSBBHCMO-KJQYFISQSA-N 11-dehydrocorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 FUFLCEKSBBHCMO-KJQYFISQSA-N 0.000 description 2
WHBHBVVOGNECLV-UHFFFAOYSA-N 11-deoxy-17-hydroxy-corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 WHBHBVVOGNECLV-UHFFFAOYSA-N 0.000 description 2
ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 2
WTPMRQZHJLJSBO-XQALERBDSA-N 11-oxotestosterone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 WTPMRQZHJLJSBO-XQALERBDSA-N 0.000 description 2
JYGXADMDTFJGBT-MKIDGPAKSA-N 11alpha-Hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-MKIDGPAKSA-N 0.000 description 2
ZHOLUHXKCIXGSR-GBHAUCNQSA-N 11alpha-Hydroxyandrosta-1,4-diene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@H](O)C[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 ZHOLUHXKCIXGSR-GBHAUCNQSA-N 0.000 description 2
JERGUCIJOXJXHF-UHFFFAOYSA-N 17alpha-Hydroxypregnenolone Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 JERGUCIJOXJXHF-UHFFFAOYSA-N 0.000 description 2
JERGUCIJOXJXHF-TVWVXWENSA-N 17alpha-hydroxypregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JERGUCIJOXJXHF-TVWVXWENSA-N 0.000 description 2
GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 2
CCCIJQPRIXGQOE-XWSJACJDSA-N 17beta-hydroxy-17-methylestra-4,9,11-trien-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C=C2 CCCIJQPRIXGQOE-XWSJACJDSA-N 0.000 description 2
DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 2
XUQWWIFROYJHCU-FJNAKSJRSA-N 18-Oxocortisol Chemical compound C([C@@]1([C@](O)(C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 XUQWWIFROYJHCU-FJNAKSJRSA-N 0.000 description 2
HFSXHZZDNDGLQN-ZVIOFETBSA-N 18-hydroxycorticosterone Chemical compound C([C@]1(CO)[C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 HFSXHZZDNDGLQN-ZVIOFETBSA-N 0.000 description 2
MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
FTMJFHVKAXPFIY-UHFFFAOYSA-N 2,2-dichloro-N-[1,3-dihydroxy-1-(3-nitrophenyl)propan-2-yl]acetamide Chemical compound OCC(NC(=O)C(Cl)Cl)C(O)c1cccc(c1)[N+]([O-])=O FTMJFHVKAXPFIY-UHFFFAOYSA-N 0.000 description 2
CRAPXAGGASWTPU-UHFFFAOYSA-N 2-deoxy-3-epiecdysone Natural products C1C(O)CCC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 CRAPXAGGASWTPU-UHFFFAOYSA-N 0.000 description 2
CRAPXAGGASWTPU-VQOIUDCISA-N 2-deoxyecdysone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 CRAPXAGGASWTPU-VQOIUDCISA-N 0.000 description 2
NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 2
HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 2
XBIDABJJGYNJTK-GNIMZFFESA-N 20beta-hydroxycortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)[C@H](O)CO)[C@@H]4[C@@H]3CCC2=C1 XBIDABJJGYNJTK-GNIMZFFESA-N 0.000 description 2
PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 description 2
LCZBQMKVFQNSJR-UJPCIWJBSA-N 21-deoxycortisol Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)C[C@@H]2O LCZBQMKVFQNSJR-UJPCIWJBSA-N 0.000 description 2
GDSSFVCRVUQMRG-IIRLTRAJSA-N 3-dehydroecdysone Chemical compound C1C(=O)[C@@H](O)C[C@]2(C)C(CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 GDSSFVCRVUQMRG-IIRLTRAJSA-N 0.000 description 2
QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 description 2
ZUDASDOHOYYFRW-UHFFFAOYSA-N 5-chloro-2-n,2-n-dimethylquinazoline-2,4-diamine Chemical compound ClC1=CC=CC2=NC(N(C)C)=NC(N)=C21 ZUDASDOHOYYFRW-UHFFFAOYSA-N 0.000 description 2
UBOIMZIXNXGQOH-RTWVSBIPSA-N 58497-00-0 Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)CC)[C@@]2(C)C[C@@H]1O UBOIMZIXNXGQOH-RTWVSBIPSA-N 0.000 description 2
VNGWBSXDGQZSFL-JMNKBGBLSA-N 6-[2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]carbonylcyclohex-3-ene-1-carboxylic acid Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)C1CC=CCC1C(O)=O VNGWBSXDGQZSFL-JMNKBGBLSA-N 0.000 description 2
IUIYEHXOIMMQJY-NGXOUOCZSA-N 60135-22-0 Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)C(OC)OC)[C@@]2(C)C[C@@H]1O IUIYEHXOIMMQJY-NGXOUOCZSA-N 0.000 description 2
GNFTWPCIRXSCQF-HVIRSNARSA-N 6alpha-Hydroxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](O)C2=C1 GNFTWPCIRXSCQF-HVIRSNARSA-N 0.000 description 2
GNFTWPCIRXSCQF-UJXAPRPESA-N 6beta-hydroxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@@H](O)C2=C1 GNFTWPCIRXSCQF-UJXAPRPESA-N 0.000 description 2
LJGWPGVRXUUNAG-UJXAPRPESA-N 6beta-hydroxyprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@@H](O)C2=C1 LJGWPGVRXUUNAG-UJXAPRPESA-N 0.000 description 2
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 description 2
IVFYLRMMHVYGJH-VLOLGRDOSA-N Bolasterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-VLOLGRDOSA-N 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 2
VWVPRYMOFYIOOZ-KAQKJVHQSA-N Cortisol octanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CCCCCCC)(O)[C@@]1(C)C[C@@H]2O VWVPRYMOFYIOOZ-KAQKJVHQSA-N 0.000 description 2
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
YCTXVPCDHZMBHX-UHFFFAOYSA-N Daturaolone Natural products C1CC(=O)C(C)(C)C2C(O)CC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC3C21C YCTXVPCDHZMBHX-UHFFFAOYSA-N 0.000 description 2
FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 2
DYCBAFABWCTLEN-PMVIMZBYSA-N Descinolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](O)[C@@](C(=O)C)(O)[C@@]1(C)C[C@@H]2O DYCBAFABWCTLEN-PMVIMZBYSA-N 0.000 description 2
WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 2
DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 2
POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 2
208000007465 Giant cell arteritis Diseases 0.000 description 2
MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
201000005569 Gout Diseases 0.000 description 2
MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 2
YCISZOVUHXIOFY-HKXOFBAYSA-N Halopredone acetate Chemical compound C1([C@H](F)C2)=CC(=O)C(Br)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@](OC(C)=O)(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O YCISZOVUHXIOFY-HKXOFBAYSA-N 0.000 description 2
206010019939 Herpes gestationis Diseases 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
JQNVCUBPURTQPQ-FTWMDKANSA-N Inokosterone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@@](O)([C@@H](O)CC[C@H](CO)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 JQNVCUBPURTQPQ-FTWMDKANSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
HUXCOHMTWUSXGY-GAPIFECDSA-N Meclorisone dibutyrate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CCC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2Cl HUXCOHMTWUSXGY-GAPIFECDSA-N 0.000 description 2
GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 description 2
UDKABVSQKJNZBH-DWNQPYOZSA-N Melengestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 UDKABVSQKJNZBH-DWNQPYOZSA-N 0.000 description 2
XWALNWXLMVGSFR-HLXURNFRSA-N Methandrostenolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 XWALNWXLMVGSFR-HLXURNFRSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 2
RXXBBHGCAXVBES-XMUHMHRVSA-N Oranabol Chemical compound C1CC2=C(O)C(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 RXXBBHGCAXVBES-XMUHMHRVSA-N 0.000 description 2
208000008223 Pemphigoid Gestationis Diseases 0.000 description 2
229930186873 Ponasterone Natural products 0.000 description 2
PJYYBCXMCWDUAZ-YKDQUOQBSA-N Ponasterone A Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@@](O)([C@@H](O)CCC(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 PJYYBCXMCWDUAZ-YKDQUOQBSA-N 0.000 description 2
LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 2
SBQAKZYUNWNIRL-WIPKXTQKSA-N Prednisolone farnesylate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)/C=C(C)/CC/C=C(C)/CCC=C(C)C)(O)[C@@]1(C)C[C@@H]2O SBQAKZYUNWNIRL-WIPKXTQKSA-N 0.000 description 2
HUMXXHTVHHLNRO-KAJVQRHHSA-N Prednisolone tebutate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC(C)(C)C)(O)[C@@]1(C)C[C@@H]2O HUMXXHTVHHLNRO-KAJVQRHHSA-N 0.000 description 2
ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 2
208000003251 Pruritus Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
PJHYXCVCRWJEMV-UHFFFAOYSA-N Rhapontisterone Natural products C1C(O)C(O)CC2(C)C(C(O)CC3(C(C(C)(O)C(O)CC(O)C(C)C)CCC33O)C)C3=CC(=O)C21 PJHYXCVCRWJEMV-UHFFFAOYSA-N 0.000 description 2
OMQCWEJQYPUGJG-UHFFFAOYSA-N Rubrosterone Natural products C1C(O)C(O)CC2(C)C3CCC(C)(C(CC4)=O)C4(O)C3=CC(=O)C21 OMQCWEJQYPUGJG-UHFFFAOYSA-N 0.000 description 2
206010039710 Scleroderma Diseases 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
XGMPVBXKDAHORN-RBWIMXSLSA-N Triamcinolone diacetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](OC(C)=O)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O XGMPVBXKDAHORN-RBWIMXSLSA-N 0.000 description 2
TZIZWYVVGLXXFV-FLRHRWPCSA-N Triamcinolone hexacetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@@H]2O TZIZWYVVGLXXFV-FLRHRWPCSA-N 0.000 description 2
201000006704 Ulcerative Colitis Diseases 0.000 description 2
206010047115 Vasculitis Diseases 0.000 description 2
IYBYNRHXGXDDDS-VRRJBYJJSA-N [(1r,4as,4bs,10ar,10bs,11s,12as)-1-acetyl-11-hydroxy-10a,12a-dimethyl-8-oxo-2,3,4,4a,4b,5,6,10b,11,12-decahydrochrysen-1-yl] butanoate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@](C(C)=O)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O IYBYNRHXGXDDDS-VRRJBYJJSA-N 0.000 description 2
KSCZWFXQKITHSL-OKCNGXCSSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6-chloro-10,13-dimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] acetate Chemical compound C1C[C@]2(C)[C@](C(C)=O)(OC(C)=O)CC[C@H]2[C@@H]2C=C(Cl)C3=C[C@@H](OC(=O)C)CC[C@]3(C)[C@H]21 KSCZWFXQKITHSL-OKCNGXCSSA-N 0.000 description 2
IWSXBCZCPVUWHT-VIFKTUCRSA-N [(8r,9s,10r,11s,13s,14s,17r)-17-acetyl-11,13-dimethyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound O=C1CC[C@@H]2[C@H]3[C@@H](C)C[C@]4(C)[C@](C(C)=O)(OC(C)=O)CC[C@H]4[C@@H]3CCC2=C1 IWSXBCZCPVUWHT-VIFKTUCRSA-N 0.000 description 2
HPFVBGJFAYZEBE-XNBTXCQYSA-N [(8r,9s,10r,13s,14s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3CC2)C)CC[C@@]11C)CC1OC(=O)CCC1CCCC1 HPFVBGJFAYZEBE-XNBTXCQYSA-N 0.000 description 2
PSJMYDLEWUWIAN-KYPKCDLESA-N [(8r,9s,10r,13s,14s,17r)-17-acetyl-6-chloro-13-methyl-3-oxo-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 PSJMYDLEWUWIAN-KYPKCDLESA-N 0.000 description 2
DPHFJXVKASDMBW-RQRKFSSASA-N [2-[(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate;hydrate Chemical compound O.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O DPHFJXVKASDMBW-RQRKFSSASA-N 0.000 description 2
YZNQMPPBWQTLFJ-TUFAYURCSA-N [2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] butanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CCC)(O)[C@@]1(C)C[C@@H]2O YZNQMPPBWQTLFJ-TUFAYURCSA-N 0.000 description 2
PHEOVVDXTQVHAZ-XDANTLIUSA-N [2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]1(C)C[C@@H]2O PHEOVVDXTQVHAZ-XDANTLIUSA-N 0.000 description 2
AKUJBENLRBOFTD-HIBZCRSPSA-N [2-[(9r,10s,11s,13s,16r,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)C1C1C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-HIBZCRSPSA-N 0.000 description 2
229960002478 aldosterone Drugs 0.000 description 2
CXDWHYOBSJTRJU-SRWWVFQWSA-N algestone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](O)[C@@](C(=O)C)(O)[C@@]1(C)CC2 CXDWHYOBSJTRJU-SRWWVFQWSA-N 0.000 description 2
229960001900 algestone Drugs 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 2
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
229950003339 amadinone Drugs 0.000 description 2
229960003099 amcinonide Drugs 0.000 description 2
ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 2
229950008564 anagestone Drugs 0.000 description 2
AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 2
229960005471 androstenedione Drugs 0.000 description 2
AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 2
229960001232 anecortave Drugs 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
MDJRZSNPHZEMJH-MTMZYOSNSA-N artisone acetate Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 MDJRZSNPHZEMJH-MTMZYOSNSA-N 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
229950000210 beclometasone dipropionate Drugs 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
RRQAFKDLLNSONH-RIWODDSKSA-M benzyl-dodecyl-dimethylazanium;4-chlorophenol;(8s,10s,13s,14s,17r)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one;5-methyl-2-propan-2-ylphenol;chloride Chemical compound [Cl-].OC1=CC=C(Cl)C=C1.CC(C)C1=CC=C(C)C=C1O.CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1.C1CC2=CC(=O)C=C[C@]2(C)C2(F)[C@@H]1[C@@H]1CC(C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2O RRQAFKDLLNSONH-RIWODDSKSA-M 0.000 description 2
NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 2
229960005354 betamethasone sodium phosphate Drugs 0.000 description 2
PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 2
229960004311 betamethasone valerate Drugs 0.000 description 2
229950008036 bolasterone Drugs 0.000 description 2
IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 2
229950009823 calusterone Drugs 0.000 description 2
239000007894 caplet Substances 0.000 description 2
229960003996 chlormadinone Drugs 0.000 description 2
VUHJZBBCZGVNDZ-TTYLFXKOSA-N chlormadinone Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 VUHJZBBCZGVNDZ-TTYLFXKOSA-N 0.000 description 2
229950006229 chloroprednisone Drugs 0.000 description 2
229960003728 ciclesonide Drugs 0.000 description 2
229960002842 clobetasol Drugs 0.000 description 2
229960004703 clobetasol propionate Drugs 0.000 description 2
229960001146 clobetasone Drugs 0.000 description 2
XXIFVOHLGBURIG-OZCCCYNHSA-N clobetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)CC2=O XXIFVOHLGBURIG-OZCCCYNHSA-N 0.000 description 2
229960004299 clocortolone Drugs 0.000 description 2
YMTMADLUXIRMGX-RFPWEZLHSA-N clocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O YMTMADLUXIRMGX-RFPWEZLHSA-N 0.000 description 2
229960001357 clocortolone pivalate Drugs 0.000 description 2
SXYZQZLHAIHKKY-GSTUPEFVSA-N clocortolone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]2(C)C[C@@H]1O SXYZQZLHAIHKKY-GSTUPEFVSA-N 0.000 description 2
229950003461 clogestone Drugs 0.000 description 2
229960002219 cloprednol Drugs 0.000 description 2
YTJIBEDMAQUYSZ-FDNPDPBUSA-N cloprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C=C(Cl)C2=C1 YTJIBEDMAQUYSZ-FDNPDPBUSA-N 0.000 description 2
230000001143 conditioned effect Effects 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 description 2
OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 2
BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 2
FZCHYNWYXKICIO-FZNHGJLXSA-N cortisol 17-valerate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O FZCHYNWYXKICIO-FZNHGJLXSA-N 0.000 description 2
229960004544 cortisone Drugs 0.000 description 2
229960003290 cortisone acetate Drugs 0.000 description 2
229960003840 cortivazol Drugs 0.000 description 2
RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 2
229950002276 cortodoxone Drugs 0.000 description 2
ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 2
FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 2
ZSAMZEYLGUEVJW-TTYLFXKOSA-N delmadinone Chemical compound C1=C(Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 ZSAMZEYLGUEVJW-TTYLFXKOSA-N 0.000 description 2
229950006309 delmadinone Drugs 0.000 description 2
229940119740 deoxycorticosterone Drugs 0.000 description 2
229950007161 deprodone Drugs 0.000 description 2
229950004709 descinolone Drugs 0.000 description 2
229960003662 desonide Drugs 0.000 description 2
WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 2
229960002593 desoximetasone Drugs 0.000 description 2
VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 2
229960003657 dexamethasone acetate Drugs 0.000 description 2
229960002344 dexamethasone sodium phosphate Drugs 0.000 description 2
PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 2
YNNURTVKPVJVEI-GSLJADNHSA-N dichlorisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2Cl YNNURTVKPVJVEI-GSLJADNHSA-N 0.000 description 2
229950009888 dichlorisone Drugs 0.000 description 2
229960004154 diflorasone Drugs 0.000 description 2
229960002124 diflorasone diacetate Drugs 0.000 description 2
229960004091 diflucortolone Drugs 0.000 description 2
OGPWIDANBSLJPC-RFPWEZLHSA-N diflucortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O OGPWIDANBSLJPC-RFPWEZLHSA-N 0.000 description 2
229960004875 difluprednate Drugs 0.000 description 2
229950009486 domoprednate Drugs 0.000 description 2
229950001255 doxibetasol Drugs 0.000 description 2
UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 2
229960003720 enoxolone Drugs 0.000 description 2
239000000945 filler Substances 0.000 description 2
BYZCJOHDXLROEC-RBWIMXSLSA-N fluazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O BYZCJOHDXLROEC-RBWIMXSLSA-N 0.000 description 2
229950002335 fluazacort Drugs 0.000 description 2
NJNWEGFJCGYWQT-VSXGLTOVSA-N fluclorolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1Cl NJNWEGFJCGYWQT-VSXGLTOVSA-N 0.000 description 2
229940094766 flucloronide Drugs 0.000 description 2
229960002011 fludrocortisone Drugs 0.000 description 2
AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 2
SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 2
229960004511 fludroxycortide Drugs 0.000 description 2
229950010349 flugestone Drugs 0.000 description 2
229960003469 flumetasone Drugs 0.000 description 2
WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 2
229940042902 flumethasone pivalate Drugs 0.000 description 2
JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 description 2
229950002998 flumoxonide Drugs 0.000 description 2
229940043075 fluocinolone Drugs 0.000 description 2
229960001347 fluocinolone acetonide Drugs 0.000 description 2
229960000785 fluocinonide Drugs 0.000 description 2
XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 description 2
229950008509 fluocortin butyl Drugs 0.000 description 2
229960003336 fluorocortisol acetate Drugs 0.000 description 2
229960001048 fluorometholone Drugs 0.000 description 2
FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 2
229960001629 fluorometholone acetate Drugs 0.000 description 2
YRFXGQHBPBMFHW-SBTZIJSASA-N fluorometholone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 YRFXGQHBPBMFHW-SBTZIJSASA-N 0.000 description 2
YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 2
229960001751 fluoxymesterone Drugs 0.000 description 2
229960003590 fluperolone Drugs 0.000 description 2
HHPZZKDXAFJLOH-QZIXMDIESA-N fluperolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](OC(C)=O)C)(O)[C@@]1(C)C[C@@H]2O HHPZZKDXAFJLOH-QZIXMDIESA-N 0.000 description 2
229960003238 fluprednidene Drugs 0.000 description 2
YVHXHNGGPURVOS-SBTDHBFYSA-N fluprednidene Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](C(=C)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 YVHXHNGGPURVOS-SBTDHBFYSA-N 0.000 description 2
229960000618 fluprednisolone Drugs 0.000 description 2
AMVODTGMYSRMNP-GNIMZFFESA-N formebolone Chemical compound C1CC2=CC(=O)C(C=O)=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@H]2O AMVODTGMYSRMNP-GNIMZFFESA-N 0.000 description 2
229950010292 formebolone Drugs 0.000 description 2
229960004421 formestane Drugs 0.000 description 2
OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 2
229960000671 formocortal Drugs 0.000 description 2
QNXUUBBKHBYRFW-QWAPGEGQSA-N formocortal Chemical compound C1C(C=O)=C2C=C(OCCCl)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O QNXUUBBKHBYRFW-QWAPGEGQSA-N 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
229960001902 gestonorone Drugs 0.000 description 2
GTFUITFQDGVJSK-XGXHKTLJSA-N gestonorone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 GTFUITFQDGVJSK-XGXHKTLJSA-N 0.000 description 2
239000003862 glucocorticoid Substances 0.000 description 2
229960002383 halcinonide Drugs 0.000 description 2
229960002475 halometasone Drugs 0.000 description 2
GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 description 2
229950008940 halopredone Drugs 0.000 description 2
GCCIFDUTISMRTG-TUPTUZDRSA-N haloprogesterone Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C(=O)C)(Br)[C@@]2(C)CC1 GCCIFDUTISMRTG-TUPTUZDRSA-N 0.000 description 2
229950002886 haloprogesterone Drugs 0.000 description 2
FWFVLWGEFDIZMJ-FOMYWIRZSA-N hydrocortamate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CN(CC)CC)(O)[C@@]1(C)C[C@@H]2O FWFVLWGEFDIZMJ-FOMYWIRZSA-N 0.000 description 2
229950000208 hydrocortamate Drugs 0.000 description 2
229960002453 hydrocortisone aceponate Drugs 0.000 description 2
MFBMYAOAMQLLPK-FZNHGJLXSA-N hydrocortisone aceponate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]1(C)C[C@@H]2O MFBMYAOAMQLLPK-FZNHGJLXSA-N 0.000 description 2
229960001524 hydrocortisone butyrate Drugs 0.000 description 2
229960004204 hydrocortisone sodium phosphate Drugs 0.000 description 2
229960001401 hydrocortisone sodium succinate Drugs 0.000 description 2
229950006240 hydrocortisone succinate Drugs 0.000 description 2
229960000631 hydrocortisone valerate Drugs 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
229960002899 hydroxyprogesterone Drugs 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
JQNVCUBPURTQPQ-XDWLXSIGSA-N inokosterone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(CO)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 JQNVCUBPURTQPQ-XDWLXSIGSA-N 0.000 description 2
229960002857 isoflupredone Drugs 0.000 description 2
229960003317 isoflupredone acetate Drugs 0.000 description 2
229950002955 isoprednidene Drugs 0.000 description 2
WSBAGDDNVWTLOM-UHFFFAOYSA-N lesterone Natural products C1C(O)C(O)CC2(C)C(C(O)CC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 WSBAGDDNVWTLOM-UHFFFAOYSA-N 0.000 description 2
DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 description 2
229960003744 loteprednol etabonate Drugs 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
229950001137 meclorisone Drugs 0.000 description 2
229960000606 medrogestone Drugs 0.000 description 2
HCFSGRMEEXUOSS-JXEXPEPMSA-N medrogestone Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 HCFSGRMEEXUOSS-JXEXPEPMSA-N 0.000 description 2
229960004616 medroxyprogesterone Drugs 0.000 description 2
FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 2
229960001011 medrysone Drugs 0.000 description 2
229960001786 megestrol Drugs 0.000 description 2
229960004296 megestrol acetate Drugs 0.000 description 2
229960004805 melengestrol Drugs 0.000 description 2
229910052751 metal Chemical class 0.000 description 2
239000002184 metal Chemical class 0.000 description 2
229960003377 metandienone Drugs 0.000 description 2
229960002037 methylprednisolone aceponate Drugs 0.000 description 2
DALKLAYLIPSCQL-YPYQNWSCSA-N methylprednisolone aceponate Chemical compound C1([C@@H](C)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]2(C)C[C@@H]1O DALKLAYLIPSCQL-YPYQNWSCSA-N 0.000 description 2
229960001293 methylprednisolone acetate Drugs 0.000 description 2
229960000334 methylprednisolone sodium succinate Drugs 0.000 description 2
IMBXEJJVJRTNOW-XYMSELFBSA-N methylprednisolone succinate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC(O)=O)CC[C@H]21 IMBXEJJVJRTNOW-XYMSELFBSA-N 0.000 description 2
229950009831 methylprednisolone succinate Drugs 0.000 description 2
229960001566 methyltestosterone Drugs 0.000 description 2
229950003695 metribolone Drugs 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
229960001664 mometasone Drugs 0.000 description 2
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 2
229960002744 mometasone furoate Drugs 0.000 description 2
WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 2
229960004123 mometasone furoate monohydrate Drugs 0.000 description 2
229960004911 nomegestrol Drugs 0.000 description 2
KZUIYQJTUIACIG-YBZCJVABSA-N nomegestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 KZUIYQJTUIACIG-YBZCJVABSA-N 0.000 description 2
229950010960 norgestomet Drugs 0.000 description 2
VOJYZDFYEHKHAP-XGXHKTLJSA-N norvinisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C=C)[C@@H]4[C@@H]3CCC2=C1 VOJYZDFYEHKHAP-XGXHKTLJSA-N 0.000 description 2
229950004927 norvinisterone Drugs 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
229950008280 oxymesterone Drugs 0.000 description 2
229960002858 paramethasone Drugs 0.000 description 2
229960000865 paramethasone acetate Drugs 0.000 description 2
150000003102 ponasterones Chemical class 0.000 description 2
229960002847 prasterone Drugs 0.000 description 2
229960002794 prednicarbate Drugs 0.000 description 2
FNPXMHRZILFCKX-KAJVQRHHSA-N prednicarbate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O FNPXMHRZILFCKX-KAJVQRHHSA-N 0.000 description 2
ILZSJEITWDWIRX-FOMYWIRZSA-N prednisolamate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CN(CC)CC)(O)[C@@]1(C)C[C@@H]2O ILZSJEITWDWIRX-FOMYWIRZSA-N 0.000 description 2
229950011122 prednisolamate Drugs 0.000 description 2
229960002800 prednisolone acetate Drugs 0.000 description 2
229950011084 prednisolone farnesylate Drugs 0.000 description 2
229960002943 prednisolone sodium phosphate Drugs 0.000 description 2
VJZLQIPZNBPASX-OJJGEMKLSA-L prednisolone sodium phosphate Chemical compound [Na+].[Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 VJZLQIPZNBPASX-OJJGEMKLSA-L 0.000 description 2
RBJROVWIRLFZFC-PNLFXGMVSA-N prednisolone steaglate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)COC(=O)CCCCCCCCCCCCCCCCC)(O)[C@@]1(C)C[C@@H]2O RBJROVWIRLFZFC-PNLFXGMVSA-N 0.000 description 2
229950010987 prednisolone steaglate Drugs 0.000 description 2
APGDTXUMTIZLCJ-CGVGKPPMSA-N prednisolone succinate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 APGDTXUMTIZLCJ-CGVGKPPMSA-N 0.000 description 2
229950004597 prednisolone succinate Drugs 0.000 description 2
229960004259 prednisolone tebutate Drugs 0.000 description 2
BOFKYYWJAOZDPB-FZNHGJLXSA-N prednival Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O BOFKYYWJAOZDPB-FZNHGJLXSA-N 0.000 description 2
229950000696 prednival Drugs 0.000 description 2
229960001917 prednylidene Drugs 0.000 description 2
WSVOMANDJDYYEY-CWNVBEKCSA-N prednylidene Chemical group O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](C(=C)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WSVOMANDJDYYEY-CWNVBEKCSA-N 0.000 description 2
229960000249 pregnenolone Drugs 0.000 description 2
ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 description 2
229950000504 procinonide Drugs 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
229960001584 promegestone Drugs 0.000 description 2
QFFCYTLOTYIJMR-XMGTWHOFSA-N promegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)CC)(C)[C@@]1(C)CC2 QFFCYTLOTYIJMR-XMGTWHOFSA-N 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
PJHYXCVCRWJEMV-XYFSXPBDSA-N rhapontisterone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H]([C@H](O)C[C@@]3([C@@H]([C@@](C)(O)[C@H](O)C[C@H](O)C(C)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 PJHYXCVCRWJEMV-XYFSXPBDSA-N 0.000 description 2
229960001487 rimexolone Drugs 0.000 description 2
QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 2
JOFBZBDWOWPUMO-QARKFJNLSA-N roxibolone Chemical compound C1CC2=CC(=O)C(C(O)=O)=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O JOFBZBDWOWPUMO-QARKFJNLSA-N 0.000 description 2
229950005377 roxibolone Drugs 0.000 description 2
OMQCWEJQYPUGJG-DTDIXVHCSA-N rubrosterone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@]4(O)C3=CC(=O)[C@@H]21 OMQCWEJQYPUGJG-DTDIXVHCSA-N 0.000 description 2
201000000306 sarcoidosis Diseases 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
206010043207 temporal arteritis Diseases 0.000 description 2
229960004631 tixocortol Drugs 0.000 description 2
YWDBSCORAARPPF-VWUMJDOOSA-N tixocortol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CS)[C@@H]4[C@@H]3CCC2=C1 YWDBSCORAARPPF-VWUMJDOOSA-N 0.000 description 2
LZSOOHLAZHOTHJ-GUCLMQHLSA-N topterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](CCC)(O)[C@@]1(C)CC2 LZSOOHLAZHOTHJ-GUCLMQHLSA-N 0.000 description 2
229950000064 topterone Drugs 0.000 description 2
OGZHZYVCWDUIJV-VSXGLTOVSA-N tralonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CF)[C@@]2(C)C[C@@H]1Cl OGZHZYVCWDUIJV-VSXGLTOVSA-N 0.000 description 2
229950004108 tralonide Drugs 0.000 description 2
DZQIYNZZUKIZNS-RCFDOMGHSA-N triamcinolone acetonide 21-palmitate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)CCCCCCCCCCCCCCC)[C@@]1(C)C[C@@H]2O DZQIYNZZUKIZNS-RCFDOMGHSA-N 0.000 description 2
GUYPYYARYIIWJZ-CYEPYHPTSA-N triamcinolone benetonide Chemical compound O=C([C@]12[C@H](OC(C)(C)O1)C[C@@H]1[C@@]2(C[C@H](O)[C@]2(F)[C@@]3(C)C=CC(=O)C=C3CC[C@H]21)C)COC(=O)C(C)CNC(=O)C1=CC=CC=C1 GUYPYYARYIIWJZ-CYEPYHPTSA-N 0.000 description 2
229950006782 triamcinolone benetonide Drugs 0.000 description 2
229960004320 triamcinolone diacetate Drugs 0.000 description 2
229960004221 triamcinolone hexacetonide Drugs 0.000 description 2
JUNDJWOLDSCTFK-MTZCLOFQSA-N trimegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](O)C)(C)[C@@]1(C)CC2 JUNDJWOLDSCTFK-MTZCLOFQSA-N 0.000 description 2
229950008546 trimegestone Drugs 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
WSBAGDDNVWTLOM-XHZKDPLLSA-N turkesterone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H]([C@H](O)C[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 WSBAGDDNVWTLOM-XHZKDPLLSA-N 0.000 description 2
DXGPJKXCWRHUMH-UHFFFAOYSA-N turkesterone Natural products C1C(O)C(O)CC2(C)C(C(O)CC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 DXGPJKXCWRHUMH-UHFFFAOYSA-N 0.000 description 2
229950008396 ulobetasol propionate Drugs 0.000 description 2
BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 description 2
229940070710 valerate Drugs 0.000 description 2
ZYTXTXAMMDTYDQ-DGEXFFLYSA-N vamorolone Chemical compound C([C@H]12)CC3=CC(=O)C=C[C@]3(C)C1=CC[C@@]1(C)[C@H]2C[C@@H](C)[C@]1(O)C(=O)CO ZYTXTXAMMDTYDQ-DGEXFFLYSA-N 0.000 description 2
QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 2
QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 2
SQPRYYSTJMNHSK-ILNISADRSA-N (8s,9s,10r,11s,13s,14s,16r,17s)-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 SQPRYYSTJMNHSK-ILNISADRSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
208000026872 Addison Disease Diseases 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
206010003827 Autoimmune hepatitis Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
208000006373 Bell palsy Diseases 0.000 description 1
206010006811 Bursitis Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
208000010007 Cogan syndrome Diseases 0.000 description 1
208000014311 Cushing syndrome Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
206010012455 Dermatitis exfoliative Diseases 0.000 description 1
208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
206010015226 Erythema nodosum Diseases 0.000 description 1
229920003137 Eudragit® S polymer Polymers 0.000 description 1
239000001263 FEMA 3042 Substances 0.000 description 1
208000001640 Fibromyalgia Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
206010018634 Gouty Arthritis Diseases 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
206010020112 Hirsutism Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
208000031814 IgA Vasculitis Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
208000005777 Lupus Nephritis Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
208000001344 Macular Edema Diseases 0.000 description 1
206010025415 Macular oedema Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
201000002481 Myositis Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010034277 Pemphigoid Diseases 0.000 description 1
201000011152 Pemphigus Diseases 0.000 description 1
LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
241001303601 Rosacea Species 0.000 description 1
102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
101710179516 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
206010039705 Scleritis Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000010265 Sweet syndrome Diseases 0.000 description 1
201000009594 Systemic Scleroderma Diseases 0.000 description 1
206010042953 Systemic sclerosis Diseases 0.000 description 1
208000001106 Takayasu Arteritis Diseases 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
206010044314 Tracheobronchitis Diseases 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
208000036826 VIIth nerve paralysis Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
206010000496 acne Diseases 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
210000004404 adrenal cortex Anatomy 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
238000004638 bioanalytical method Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
229940082252 budesonide 9 mg Drugs 0.000 description 1
208000000594 bullous pemphigoid Diseases 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
238000010411 cooking Methods 0.000 description 1
229940070947 cortisone acetate 25 mg Drugs 0.000 description 1
208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229940036831 deflazacort 6 mg Drugs 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
229940020470 dipyridamole 100 mg Drugs 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
208000004526 exfoliative dermatitis Diseases 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
229960003973 fluocortolone Drugs 0.000 description 1
GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 1
201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
206010061989 glomerulosclerosis Diseases 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
229940082232 hydrocortisone 20 mg Drugs 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000036971 interstitial lung disease 2 Diseases 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
230000007794 irritation Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
201000011486 lichen planus Diseases 0.000 description 1
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000010230 macular retinal edema Diseases 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229940049920 malate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000002395 mineralocorticoid Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
230000000050 nutritive effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
230000037361 pathway Effects 0.000 description 1
201000001976 pemphigus vulgaris Diseases 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
YXJYBPXSEKMEEJ-UHFFFAOYSA-N phosphoric acid;sulfuric acid Chemical compound OP(O)(O)=O.OS(O)(=O)=O YXJYBPXSEKMEEJ-UHFFFAOYSA-N 0.000 description 1
201000006292 polyarteritis nodosa Diseases 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229940095453 prednisone 10 mg Drugs 0.000 description 1
201000009395 primary hyperaldosteronism Diseases 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
230000009467 reduction Effects 0.000 description 1
208000009169 relapsing polychondritis Diseases 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
201000004700 rosacea Diseases 0.000 description 1
238000007789 sealing Methods 0.000 description 1
238000009517 secondary packaging Methods 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
235000011888 snacks Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000005563 spheronization Methods 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
235000015523 tannic acid Nutrition 0.000 description 1
229920002258 tannic acid Polymers 0.000 description 1
LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
229940033123 tannic acid Drugs 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
229940016054 triamcinolone 4 mg Drugs 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
238000009736 wetting Methods 0.000 description 1
235000008939 whole milk Nutrition 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1